LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Home・Akcijų sąrašas・MannKind Corp

MannKind Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

3.57 5

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.39

Max

3.59

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-671K -17M
Pardavimai	-22M 90M
P/E Sektoriaus vid.	140.5 49.888
Pelnas, tenkantis vienai akcijai	-0.02
Pelno marža	-18.431
Darbuotojai	591
EBITDA	5.9M 3.4M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+140.41% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	223M 1.1B
Ankstesnė atidarymo kaina	-1.43
Ankstesnė uždarymo kaina	3.57

Naujienos nuotaikos

By Acuity

17%

83%

34 / 344 reitingas Healthcare

MannKind Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-08 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

2026-06-08 15:41; UTC

Pagrindinės rinkos jėgos

American Battery Shares Jump on Energy Department Victory

2026-06-08 23:46; UTC

Rinkos pokalbiai

Nikkei May Rebound After Monday's Selloff -- Market Talk

2026-06-08 23:37; UTC

Rinkos pokalbiai

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

2026-06-08 23:25; UTC

Rinkos pokalbiai

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

2026-06-08 23:25; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-08 21:57; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

2026-06-08 21:56; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Agrees to Buy m3ter

2026-06-08 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-08 19:22; UTC

Rinkos pokalbiai

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

2026-06-08 19:01; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

2026-06-08 18:52; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-06-08 18:52; UTC

Rinkos pokalbiai

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

2026-06-08 18:17; UTC

Rinkos pokalbiai

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

2026-06-08 17:32; UTC

Rinkos pokalbiai

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

2026-06-08 17:29; UTC

Rinkos pokalbiai

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

2026-06-08 17:29; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-08 16:55; UTC

Įsigijimai, susijungimai, perėmimai

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

2026-06-08 16:54; UTC

Įsigijimai, susijungimai, perėmimai

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

2026-06-08 16:40; UTC

Rinkos pokalbiai

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

2026-06-08 16:31; UTC

Rinkos pokalbiai

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

2026-06-08 16:27; UTC

Rinkos pokalbiai

Mexican Inflation Seen Easing in May -- Market Talk

2026-06-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-08 16:03; UTC

Įsigijimai, susijungimai, perėmimai

Orange Bought Stake From Lorca

2026-06-08 16:01; UTC

Įsigijimai, susijungimai, perėmimai

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

2026-06-08 16:01; UTC

Įsigijimai, susijungimai, perėmimai

Orange Acquires 100% Ownership of MasOrange

2026-06-08 15:58; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-08 15:58; UTC

Rinkos pokalbiai

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

2026-06-08 15:55; UTC

Rinkos pokalbiai

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

2026-06-08 15:41; UTC

Rinkos pokalbiai

Gold Falls Below 200-Day Moving Average -- Market Talk

Akcijų palyginimas

Kainos pokytis

MannKind Corp Prognozė

Kainos tikslas

By TipRanks

140.41% į viršų

12 mėnesių prognozė

Vidutinis 8.15 USD 140.41%

Aukščiausias 11 USD

Žemiausias 4.75 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MannKind Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių MannKind Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

34 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.